Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01593787
- Locations
- 🇯🇵
Novartis Investigative Site, Osaka, Japan
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT01590199
- Locations
- 🇩🇪
Novartis Investigative Site, Muenster, Germany
Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.
Phase 3
Terminated
- Conditions
- Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
- Interventions
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT01589237
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Phase 3
Completed
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 423
- Registration Number
- NCT01584648
- Locations
- 🇬🇧
Novartis Investigative Site, Preston, United Kingdom
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 121
- Registration Number
- NCT01585272
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6998
- Registration Number
- NCT01585298
- Locations
- 🇩🇪
Novartis Investigative Site, Öhringen, Germany
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT01582061
- Locations
- 🇺🇸
Advanced Research, LLC, Peoria, Arizona, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
🇺🇸Diabetes and Endocrinology Associates, PC, Omaha, Nebraska, United States
Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 293
- Registration Number
- NCT01582230
- Locations
- 🇹🇭
Novartis Investigative Site, Khon Kaen, Thailand
Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT01582243
- Locations
- 🇨🇳
Novartis Investigative Site, Changhua, Taiwan
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 175
- Registration Number
- NCT01580020
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
© Copyright 2025. All Rights Reserved by MedPath